companydata.dkcompanydata.dk

Novo Nordisk Pharmatech A/S: Financial statements 2013

CVR: 13246149

Source: annual report 2013, Danish Business Authority

01/01/2013 – 31/12/2013

Novo Nordisk Pharmatech A/S (CVR 13246149) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 497,979,000 and a net result of DKK 46,703,000. The profit margin was 9.4%. Equity in the 2013 report amounted to DKK 304,474,000. The solvency ratio was 71.2%. The company had 141 employees in the financial year.

Revenue
DKK 497,979,000
Gross Profit
DKK 170,714,000
Profit/Loss
DKK 46,703,000
Equity
DKK 304,474,000
Total Assets
DKK 427,784,000
Employees
141

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

Novo Nordisk Pharmatech A/S: The 2012 annual report is outFeb 27, 2013

Novo Nordisk Pharmatech A/S has published its annual report for 2012.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 489 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.

Source: annual report 2025, Danish Business Authority